×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Q&A Session: Using Type 9 NDA Classification to Accelerate Multiple Approvals for Your Drug Product
Session Chair(s)
David Meats
Director, Regulatory Services Management
Certara, United States
Have you watched the Using Type 9 NDA Classification to Accelerate Multiple Approvals for Your Drug Product session On Demand and have questions for the speakers? Now is your chance join the speakers live for interactive questions and answers!
Speaker(s)
Panelist
Vibha Kumar, PhD
Certara Synchrogenix, United States
Associate Principal Regulatory Writer
Panelist
Elaine Taylor
Certara Synchrogenix, United States
Vice President, Regulatory Services Management
Have an account?